Clinical Trial

Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Study acronym: CCGLC-017
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients with resectable hepatocellular carcinoma (HCC) at high risk of recurrence.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Trial Details
NCT Number NCT06954116
Lead Sponsor Tongji Hospital
Collaborators: Qilu Pharmaceutical Co., Ltd.
Conditions Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Enrollment 26 participants
Start Date 2025-08-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-13